Tests two drugs together for schizophrenia in adults
Tests a sigma-1 drug combined with an NMDA-enhancing drug in people with schizophrenia.
Plain-language title generated from the registry record
Registry title: Dual Modulation of Sigma-1 and NMDA Receptors in the Treatment of Schizophrenia
Key facts
- Where
- Taichung, TaiwanSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT06574360, who can take part
Where in Taiwan
- Department of Psychiatry, China Medical University HospitalTaichung, TaiwanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- China Medical University Hospital
- Trial code
- NCT06574360
- Record updated
- 24 March 2026
- Original description
sigma-1 receptor (S1R) agonistic property have been tested in clinical trials for the treatment of schizophrenia. In addition, previous studies found that some NMDA receptor (NMDAR)-enhancing agents were able to improve clinical symptoms of patients with chronic schizophrenia. Whether combined treatment of an S1R agonist and an NMDA-enhancing agent can be better than an S1R agonist alone deserves study.Read full original descriptionShow less
Dual Modulation of Sigma-1 and NMDA Receptors in the Treatment of Schizophrenia
sigma-1 receptor (S1R) agonistic property have been tested in clinical trials for the treatment of schizophrenia. In addition, previous studies found that some NMDA receptor (NMDAR)-enhancing agents were able to improve clinical symptoms of patients with chronic schizophrenia. Whether combined treatment of an S1R agonist and an NMDA-enhancing agent can be better than an S1R agonist alone deserves study.
Inclusion: Have a DSM-5 (American Psychiatric Association) diagnosis of schizophrenia; Are resistant to adequate treatments of at least two antipsychotics (excluding clozapine); Remain symptomatic but without clinically significant fluctuation, while their antipsychotic doses are unchanged for at least 3 months and will be maintained during the period of the 8-week trial; PANSS total score >70; Hamilton Depression Rating Scale-17 items (HAMD) <7; Are physically healthy and laboratory assessments (including blood routine, biochemical tests) are clinically insignificant; Have sufficient education to communicate effectively and are capable of completing the assessments of the study; Agree to participate in the study and provide informed consent.
Exclusion: DSM-5 diagnosis of intellectual disability or substance (including alcohol) use disorder; History of epilepsy, head trauma, central nervous system diseases or mental disorders other than schizophrenia (including major depressive disorder, bipolar disorders, persistent depressive disorder, obsessive-compulsive disorder); Pregnancy or lactation; Inability to follow protocol.